Literature DB >> 30379740

Safety of Therapeutic Plasma Exchange for the Treatment of Guillain-Barré Syndrome in Polycythemia Vera.

Rory M C Abrams1, Gregory A Elder1,2.   

Abstract

Polycythemia vera (PV) is a risk factor for systemic thromboses and ischemic stroke. This has been attributed to blood hyperviscosity, the result of increased blood cell production. Intravenous immunoglobulin, which is indicated for the treatment of numerous hematologic and neurological conditions also causes increased serum viscosity and has been associated with ischemic strokes in the setting of PV. Here we report a case of a 70-year-old man with prior stroke and PV who developed Guillain-Barré syndrome, an acute inflammatory demyelinating disorder of peripheral nerves causing ascending paresis, numbness, and paresthesia, who was treated safely with therapeutic plasma exchange. Plasma exchange may be preferable to administration of intravenous immunoglobulin for treatment of various medical conditions in patients with comorbid PV.

Entities:  

Mesh:

Year:  2018        PMID: 30379740     DOI: 10.1097/NRL.0000000000000197

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  2 in total

1.  Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease.

Authors:  Rory M C Abrams; Brian D Kim; Desiree M Markantone; Kaitlin Reilly; Alberto E Paniz-Mondolfi; Melissa R Gitman; S Yoon Choo; Winona Tse; Jessica Robinson-Papp
Journal:  J Neurovirol       Date:  2020-07-27       Impact factor: 3.739

2.  Guillain-Barre Syndrome, Facial Diplegia, and Pfizer COVID-19 Vaccine.

Authors: 
Journal:  J Emerg Med       Date:  2021-10-29       Impact factor: 1.484

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.